ANI executive reports tax-related share dispositions

ANI Pharmaceuticals’ SVP and Chief HR Officer Krista Davis reported tax-related share dispositions connected to restricted stock vesting.

Rhea-AI Filing Summary

ANI Pharmaceuticals’ SVP and Chief HR Officer Krista Davis reported tax-related share dispositions connected to restricted stock vesting. On February 12, 2026, 1,180 shares of common stock were disposed of at $76.70 per share for tax withholding, leaving 54,367 shares held directly. On February 14, 2026, a further 1,290 shares were disposed of at $77.36 per share for tax withholding, resulting in 53,077 common shares held directly afterward. The footnotes state these were shares withheld for taxes upon vesting of 3,264 and 3,020 restricted stock shares previously granted.

Insider Trade Summary

Exercise Price or Tax Liability: 2,470 shares

Exercise Price or Tax Liability 2 txns

Insider Davis Krista

Role SVP, CHIEF HR OFFICER

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,290	$77.36	$100K
Exercise Price or Tax Liability	Common Stock	1,180	$76.70	$91K

Holdings After Transaction: Common Stock — 53,077 shares (Direct)

Footnotes (2)

1. F1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,264 shares of restricted stock, the grant of which was previously reported on February 18, 2025.
2. F2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,020 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANIP executive Krista Davis report on this Form 4?

Krista Davis reported two tax-withholding share dispositions of ANI Pharmaceuticals common stock. On February 12 and 14, 2026, shares were withheld to cover tax obligations arising from vesting restricted stock, rather than being open-market sales.

How many ANI Pharmaceuticals (ANIP) shares were disposed of for taxes by Krista Davis?

Krista Davis had 1,180 shares disposed of on February 12, 2026, at $76.70 and 1,290 shares disposed of on February 14, 2026, at $77.36. Both transactions were tax-withholding dispositions related to restricted stock vesting.

How many ANIP shares does Krista Davis hold after the reported Form 4 transactions?

After the February 14, 2026 tax-withholding disposition, Krista Davis directly holds 53,077 shares of ANI Pharmaceuticals common stock. This reflects her updated direct ownership following the restricted stock vesting-related tax transactions.

Were the ANIP insider transactions open-market buys or sells by Krista Davis?

The transactions were not open-market buys or sells. They are coded “F,” indicating shares were disposed of to pay tax liabilities in connection with vesting restricted stock awards, as noted in the accompanying explanatory footnotes.

What restricted stock vestings triggered the ANIP tax-withholding share dispositions?

The footnotes explain that shares were withheld for taxes upon vesting of 3,264 restricted stock shares from a grant reported February 18, 2025, and 3,020 restricted stock shares from a grant reported February 16, 2024.

What role does Krista Davis hold at ANI Pharmaceuticals (ANIP) in this Form 4?

Krista Davis is identified as an officer of ANI Pharmaceuticals, serving as Senior Vice President and Chief Human Resources Officer. The Form 4 reflects changes in her direct beneficial ownership of the company’s common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Krista

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF HR OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		F(1)		1,180	D	$76.7	54,367	D
Common Stock	02/14/2026		F(2)		1,290	D	$77.36	53,077	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,264 shares of restricted stock, the grant of which was previously reported on February 18, 2025.

2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,020 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

Remarks:

	/s/ Krista Davis, by attorney-in-fact Meredith W. Cook	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.